



Review

The prolactin receptor: Diverse and emerging roles in pathophysiology



Caroline M. Gorvin*

Academic Endocrine Unit, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Oxford, OX3 7LJ, UK

ARTICLE INFO

Article history:

Received 5 May 2015

Accepted 10 May 2015

Keywords:

Hyperprolactinemia

Diabetes

Tumorigenesis

Reproduction

Immunity

ABSTRACT

Investigations over two decades have revised understanding of the prolactin hormone. Long thought to be merely a lactogenic hormone, its list of functions has been extended to include: reproduction, islet differentiation, adipocyte control and immune modulation. Prolactin functions by binding cell-surface expressed prolactin receptor, initiating signaling cascades, primarily utilizing Janus kinase-signal transducer and activator of transcription (JAK-STAT). Pathway disruption has been implicated in tumorigenesis, reproductive abnormalities, and diabetes. Prolactin can also be secreted from extrapituitary sources adding complexity to understanding of its physiological functions. This review aims to describe how prolactin exerts its pathophysiological roles by endocrine and autocrine means.

© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The hormone prolactin has long been recognized for its role in lactation. However, evidence has emerged of its more promiscuous nature, with proposed functions as diverse as islet differentiation, immune modulation, adipocyte control and reproduction (Fig. 1). With such a variety of functions reputedly contributed to by prolactin it is perhaps unsurprising that its receptor, the prolactin receptor (PRLR), is expressed on diverse tissues [1–6]. The PRLR is a type-I cytokine receptor that signals predominantly via the JAK2-STAT5 signaling pathway, but is capable of initiating other signal cascades [7]. The structure and signaling pathways of prolactin and its receptor have been the focus of several excellent reviews [7,8] and therefore will not be the focus of this review. Instead, the pathophysiological roles of prolactin will be discussed, taking into consideration both its endocrine role, when produced by the pituitary, and its autocrine role, when produced locally by tissues.

Role of PRLR in lactation and reproduction

A role for prolactin in lactation has been established for decades, yet new insights continue to emerge. Prolactin plays a crucial role in two reproductive functions: mammary gland development during late gestation and the early post-partum period, and formation of the corpus luteum following blastocyst implantation [9,10].

During pregnancy the mammary gland undergoes extensive ductal side-branching and alveolar budding evolving to a milk-secreting gland [11]. Prolactin contributes to both proliferation and differentiation of mammary tissue [12]. *Prlr*^{-/-} mice do not develop mammary gland terminal-end buds and are unable to lactate, similarly to *Jak2*-conditional and *Stat5a*-conventional knockout mice [13–17]. Impairment of mammary gland development is not as severe in *Stat5b*-null mice, but milk protein production is affected, demonstrating both STAT5 components are necessary for lactation [18,19]. Furthermore, these studies suggest that other PRLR-mediated signaling pathways, and PRLR-independent pathways, are unable to fully compensate for the JAK-STAT pathway in mammary gland function.

Both long and short forms of PRLR are required for milk protein expression and lactation [20]. Initial studies of *Prlr*^{+/-} mice demonstrated impaired mammary gland alveolar differentiation and failure to lactate on first pregnancy, but recovery on subsequent pregnancies [15,16,21,22]. However, later investigations showed this recovery may be mouse strain dependent as breeding onto a pure C57BL/6 background could not rescue heterozygous lactation in most animals [23]. Mammary gland developmental defects observed in *Prl*^{-/-} and *Prlr*^{-/-} mice are largely mediated by loss of the progesterone surge in early pregnancy [16,24]. Treatment of mice with progesterone restores ductal side-branching defects [15].

The progesterone surge is produced by the corpus luteum, and is necessary for decidualization of endometrial tissue [10]. PRLR expression increases at decidualization [10,25] and prolactin stimulates progesterone secretion and progesterone receptor expression on uterine epithelium, providing favorable conditions for implantation

* Corresponding author.

E-mail address: caroline.gorvin@ocdem.ox.ac.uk.




Fig. 1. Summary of the diverse functions of the PRLR. The PRLR is proposed to have a role in reproduction, islet differentiation, regulation of fat stores and immune responses. PRLR is expressed on mammary gland cells, pancreatic β -cells, adipocytes and immune cells. Prolactin secreted by the pituitary gland has a number of physiological effects on these tissues (black text). Prolactin can also be secreted by cells within these tissues, leading to autocrine effects. Impairments of these functions due to mutation of the receptor, or changes in expression, may lead to pathological states (green text).

[8,26]. Prolactin reduces the frequency and amplitude of luteinizing hormone pulses by direct actions on gonadotropin-releasing hormone neurons, and indirectly via γ -aminobutyric acid and kisspeptin neurons [27]. *Prlr*^{-/-} female mice are hyperprolactinemic and infertile [16]. Egg development, ovulation and blastocyst implantation are reduced in *Prlr*-null mice [16,21,24,26]. In addition, corpus luteal formation is regressed in early pregnancy and progesterone production reduced [26]. As in the mammary gland, progesterone administration is able to rescue these phenotypes in *Prlr*^{-/-} mice [28]. Full corpus luteal formation requires both STAT5a and STAT5b as double knockout mice are infertile, with no corpus luteum, while single knockouts retain some fertility [18,19,29]. Autocrine prolactin produced by uterine cells may also have a function in maintenance of the corpus luteum following initial formation [10].

Hyperprolactinemic patients have variable reproductive abnormalities. 40% of hyperprolactinemic women have amenorrhea [27], other patients have galactorrhea, infertility or hypogonadism [30]. The variability in reproductive abnormalities in humans is reflected in the recently reported hyperprolactinemic family, which harbor a heterozygous PRLR-H188R loss-of-function mutation [31]. The three sisters reported in this study had a shared phenotype of oligomenorrhea, with galactorrhea and infertility also reported [31]. This infertility was not accompanied by abnormal ovulation, and luteal phase progesterone levels were normal [31]. Differences in reproductive abnormalities in patients could stem from different causes of hyperprolactinemia, utilization of different PRLR isoforms, or in the case of this family, from the heterozygous nature of the mutation. Discovery of further families with PRLR mutations could yield further insights into these differences.

Prolactin is less abundant in males than females, consistent with the hormone's primary role in lactation. However, male-specific roles may exist. Hyperprolactinemic patients experience erectile dysfunction (16%) and oligospermia (10%) [27]. *Prl*-null mice have reduced ventral prostate weight compared to wild-type littermates, and mice overexpressing prolactin have prostate hyperplasia [32,33]. Similarly, rats with chronic hyperprolactinemia have prostate enlargement [34]. However, *Prlr*^{-/-} mice have normal plasma testosterone levels and testicular weights [35] and despite a reduced ability to produce a first pregnancy in *Prlr*^{-/-} male mice, subsequent matings were successful [36].

Role of PRLR in tumourigenesis

Elevated PRLR expression and high circulating levels of prolactin have been associated with increased risk of tumor progression and invasion [37–39]. Prospective studies demonstrate up to 95% of female mammary tumors, and 60% of male breast carcinomas express prolactin and/or PRLR [40–42]. This association is replicated in animal models including transgenic mice overexpressing prolactin that develop mammary carcinoma [43,44]. In humans, a direct correlation between single nucleotide polymorphisms (SNPs) in *PRL* and/or *PRLR* and tumor incidence has been sought. Many of these studies failed to identify associations [45–48], however two SNPs, PRLR-I70V and I146L, demonstrate constitutive receptor activity, with one correlating with the occurrence of benign breast disease in a patient cohort [49]. However, these patients did not have elevated serum prolactin, nor did they have differences in other clinical parameters investigated [49,50]. Furthermore, other studies in which

these variants were identified failed to correlate their appearance with cancer prognosis, casting doubt on their importance in neoplasia, not least because of their high prevalence in the normal population [31,46,48]. Other non-coding SNPs in *PRL* or *PRLR* have been associated with breast cancer, however their functional effects are unknown [47,51]. Larger cohorts of cancer patients and a better understanding of PRLR variants across normal populations are required to better understand its role in pathogenesis.

The molecular mechanisms by which prolactin exerts mitogenic actions are being explored, and it is likely multiple complex pathways are involved. This is complicated further by emerging hypotheses that prolactin may alter its signal transduction pathways in breast carcinogenesis. Thus many breast tumors are characterized by reduced STAT5 despite high levels of PRLR expression [52,53]. Often these tumor subtypes: exhibit high levels of mitogen-activated protein kinase (MAPK) signal components including activator protein-1 (AP-1) and pro-invasive matrix metalloproteinases (MMPs); are highly invasive; are associated with resistance to chemotherapy and anti-estrogen treatments; and have a poor prognosis [54]. The tumor microenvironment may be responsible for favoring one signal pathway over another [55]. Stiff collagen matrices are associated with invasive breast cancer [55] and shift prolactin signaling profiles from STAT5-mediated pathways to focal-adhesion kinase and MAPK pathways, favoring proliferation [55]. Furthermore, prolactin signals in high-density matrices, increased MMP expression and favored a disorganized structure allowing for cellular motility [55]. Blocking JAK2 had a similar effect, elevating extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor- β favoring epithelial-mesenchymal-transition and tumor metastasis [56].

The tumor microenvironment potentially holds the key to deciphering the complex interplay between PRLR and estrogen receptor (ER α). Whilst expression of ER α or PRLR alone had no effect on tumor progression, co-expression of PRLR and ER α within a non-compliant, stiff matrix is associated with increased invasiveness in tumor cell models and reduced responsiveness to estrogen antagonists [57]. Furthermore, co-operativity between the two pathways exists with each hormone inducing expression of the reciprocal receptors in cellular studies [58–60].

Other molecular markers of breast cancer exist within the PRLR pathway. PRLR turnover mediated by phosphorylation of S349 is critical in preventing long-term stabilization of the receptor that favors tumor progression [41]. Receptors resistant to degradation had higher levels of MMP9 and exhibited invasive behaviors [41,61]. A novel protein partner of the PRLR, calcium-modulating cyclophilin ligand (CAML), is highly expressed in breast cancer [62]. CAML acts as a scaffold protein, prolonging PRLR interaction with signal transduction components, and increasing proliferation [62]. Studies have also revealed an intrinsic component of the PRLR pathway may contribute to understanding of prolactin's role in tumorigenesis. The STAT5 proteins, STAT5a and STAT5b, though highly related, have distinct expression patterns in breast tumors where nuclear STAT5a is reduced, while STAT5b remains unchanged [63]. This low level of STAT5a was associated with poor prognosis [63], indicating it could act as a novel biomarker to predict tumor outcomes. This finding may explain some of the conflicting reports regarding STAT5 expression in breast cancer, as commonly used antibodies often cannot distinguish between STAT5a and STAT5b proteins [63].

Investigation of the neoplastic role of prolactin has been further hampered by the indiscriminate study of global prolactin, without consideration of prolactin produced by the mammary gland [64]. Autocrine prolactin production has been shown in human breast tissue [65,66], and in mouse models (following hypophysectomy [65], and in the transgenic NRL-PRL mouse model that enriches prolactin within the mammary environment, while retaining

normal global prolactin levels) [59,67]. In NRL-PRL female mice estrogen treatment, although not necessary for tumor development, enhances prolactin-induced tumorigenesis [68]. However, one study examining breast cancer tumors and cell-lines was unable to detect elevated prolactin [44], concluding that autocrine prolactin may not be important in all patients.

The prolactin autocrine-paracrine loop may play a role in male breast carcinoma [40] and other reproductive cancers including cervical [69] and prostate cancer [34,40]. Evidence for this autocrine role is provided by transgenic mice overexpressing *Pr1* under a prostate-specific promoter (Pb-PRL) that developed prostate hyperplasia in the absence of elevated serum androgen levels [70].

There is still much to be learned about the role of prolactin and its receptor in tumorigenesis. It is likely further investigation of the tumor microenvironment and the effects of autocrine-paracrine signaling will yield new avenues of investigation. Further, a greater understanding of the molecular signatures of breast tumors could highlight new therapeutic targets, yielding fresh hope for drugs targeting PRLR pathways that have thus far produced poor results [67].

Role of PRLR in islet proliferation

The PRLR is highly expressed at the pancreatic β -cell, and may play a fundamental role in the β -cell expansion that occurs to meet increased metabolic demands required during pregnancy [5,71]. Correlations between the rise in β -cell mass and the mid-pregnancy lactogenic surge led to the hypothesis that prolactin and placental lactogen drives this β -cell differentiation [5,71]. In support of this hypothesis cellular studies show the lactogenic hormones increase PRLR expression on β -cells, induce β -cell replication and increase glucose-stimulated insulin secretion (GSIS) [5,72] *In vivo* studies provide further evidence. *Prlr*^{-/-} mice had reduced β -cell mass, reduced islet density, impaired glucose tolerance, reduced insulin secretion, and islets contain 20–35% less insulin [5]. Heterozygous mice similarly had impaired glucose tolerance, which was affected by maternal genotype, with more pronounced impairments in those with heterozygous mothers [5]. This is reminiscent of human gestational diabetes in which it has been observed that prenatal exposure to gestational diabetes increases its risk in the next generation [73].

In vitro and *in vivo* studies have provided a wealth of data on prolactin's effect on pancreatic islets allowing rudimentary pathway insights. Prolactin largely regulates its functions on the pancreatic β -cell via the JAK2-STAT5 pathway [74]. Cells infected with Ad-shSTAT5b that silences STAT5b, displayed reduced insulin signaling [75]. Furthermore, mice injected with Ad-shSTAT5b had reduced glucose tolerance, glucose clearance and insulin signaling in the liver [75]. Mice in which pancreatic β -cell *Stat5a/b* has been deleted exhibit no discernible defects in β -cell development, but aged and pregnant mice are mildly glucose intolerant [76]. This phenotype was milder than that observed in *Prlr*-null mice indicating STAT5 alone is not responsible for all prolactin-mediated effects on β -cells.

The activated PRLR acts as a hub to nucleate proteins from diverse signaling pathways. The insulin-related substrate proteins (IRS1-3) are one such protein family that act as signal adapters allowing recruitment of Akt and phosphoinositide-3 kinase (PI3K), that activate further signal cascades (e.g. MAPK) and gene transcription. Prolactin induces phosphorylation of all three IRS proteins, most likely via JAK2 [77]. Anti-sense PRLR blocks this prolactin-induced increase in IRS1/2, Akt and ERK1/2 phosphorylation [78].

Downstream targets of these prolactin-induced pathways include glucokinase [79] and cell-cycle proteins (e.g. cyclin-D2) [71,80] and transcription factors (e.g. forkhead-box protein D3 (FOXO3)) [81]. Glucokinase regulates the rate-limiting step in glucose metabolism [79]. Its expression is increased in

prolactin-treated cells, even in the absence of glucose [79]. This mechanism is STAT5-dependent and leads to increased insulin secretion [79]. PRLR-siRNA treatment reduces cyclin-D2 expression in INS-1 cells [71,80] and cyclin-D2 knockout mice are glucose-intolerant [82]. However, *Prlr*^{+/-} mice had normal *CCND2* expression levels [83]. Pancreas-specific deletion of *FoxD3* leads to gestational diabetes in mice characterized by impaired glucose tolerance, reduced β -cell mass and reduced β -cell proliferation [81]. The wild-type offspring of *Prlr*^{+/-} mice have reduced *FoxD3* and decreased Akt phosphorylation [73], indicating FOXD3 is a major driver of Akt-mediated β -cell proliferation [73].

PRLR may mediate its effect on islets in part by regulating the tumor suppressor protein menin. In the normal state, menin regulates expression of the cyclin-dependent kinase p27 and p18, whose function is to inhibit islet proliferation [84]. However, in the pregnant state, menin, p27 and p18 are reduced, which coincides with the increased proliferation observed in pancreatic β -cells [83]. *Prlr*^{+/-} mice also have elevated p18 and fail to increase IRS2 and Akt expression [83]. These findings, when considered in light of previous findings that prolactin increases BCL6-mediated repression of MEN1 transcription via STAT5 activation [84], indicate that the reduced β -cell mass observed in *Prlr*^{+/-} mice may be mediated by prolactin's action on menin, via Akt and JAK-STAT pathways within pancreatic β -cells.

Other regulators of the prolactin-induced effects during pregnancy have emerged recently, though their precise roles remain controversial. These include the enzyme tryptophan hydroxylase (*Tph1*) that regulates the rate-limiting step in serotonin synthesis that was reported to be increased during pregnancy [85]. Mice fed a low-tryptophan diet had mild gestational glucose intolerance [85]. Furthermore, prolactin treatment was shown to increase *Tph1* expression and serotonin synthesis during pregnancy [85], whilst PRLR knockdown in insulinoma cells reduced *Tph1* expression [71]. This led to the proposed model in which lactogenic hormones drive the expression of *Tph1* and its receptor on target cells leading to G_{α_q} -mediated activation of β -cell proliferation during pregnancy, followed by G_{α_i} -mediated inhibition of β -cell proliferation in the post-partum period [85]. Although, Schraenen et al. [86], were able to demonstrate a similar increase in *Tph1* induction by PRLR-JAK2-STAT5 in a subset of islets, they observed no differences in β -cell proliferation in *Tph1*-null mice compared to control mice [86]. Such discrepancies may lie in the mouse strains used to study these effects as proposed recently by Goyvaerts et al. [87]. Alternatively, the serotonin-induced effects may be mediated via a different mechanism, such as the β -cell expressed serotonin-gated cation channel that has been shown to depolarize the β -cell membrane, thus lowering the threshold for glucose-stimulated insulin secretion required during pregnancy [88]. Such findings have highlighted the requirement for further investigation of the function of serotonin in human islets, and the role PRLR plays.

In spite of growing evidence that prolactin plays a critical role in regulating β -cell changes observed in pregnancy, a convincing role in man has yet to be identified. Studies of chronic hyperprolactinemia demonstrate patients have postprandial hyperinsulinaemia and an exaggerated insulin secretory response to glucose [89]. Furthermore, significant associations between two PRLR SNPs and gestational diabetes mellitus have been shown [90]. However, other studies could not demonstrate similar effects, possibly due to the complex cross-talk between PRLR and insulin receptor. Further research is required to determine the role, if any, that prolactin plays in human pancreatic adaptation to pregnancy.

Role of PRLR in adipose tissue

In a situation analogous to that of the pancreatic islet, the adipocytes must undergo extensive changes during pregnancy and

lactation, comprising neuronal changes that permit increased food intake, and fat store redistribution to satisfy energy demands [91]. During these periods fat store distribution shifts from abdominal tissues to mammary glands [91]. Coincident with this fat redistribution is the lactogenic surge at mid-to-late pregnancy, implicating a role for prolactin in this process. *Prlr*^{-/-} mice have reduced weight gain after 16 weeks which is more obvious in females [92]. Consequently abdominal fat stores are reduced and fasting plasma levels of the adipocyte hormone leptin are reduced in *Prlr*^{-/-} female mice [92].

The role of prolactin in adipocyte differentiation in brown adipose tissue (BAT) has been investigated [93]. BAT mediates adaptive thermogenesis, a process required for thermoregulation in neonates. The protein UCP1 plays a critical role in this process by shifting proton gradients generated at the inner mitochondrial membrane from energy production to generate heat [94]. BAT mass in neonate PRLR-null mice was significantly reduced compared to wild-type littermates, and brown adipocytes had decreased triglyceride content [93]. Furthermore, these mice were more sensitive to a cold challenge, and had reduced expression of uncoupling protein-1 (UCP1), known to be involved in the thermogenesis process, as well as genes involved in adipocyte differentiation (e.g. peroxisome proliferator-activated receptor- γ (PPAR γ)) [93]. *Prlr*^{-/-} neonates had smaller mitochondria in BAT. PRLR overexpression rescued BAT differentiation in immortalized preadipocytes and restored PRLR, UCP1 and PPAR γ protein expression illustrating the critical role for PRLR in regulation of BAT differentiation. Furthermore, the authors demonstrated that IGF2 may mediate the growth of adipocytes downstream of PRLR-STAT5 [93].

Modulation of food intake is partially controlled by the hormone leptin whose receptor shares signaling pathways with PRLR. During lactation, plasma leptin levels reduce by 40% [92]. Furthermore, rats and mice have gestational leptin-resistance attributed to the lactogenic surge that occurs at this period [95]. The prolactin receptor and leptin receptor share expression sites within the hypothalamus and brainstem, thus crosstalk may exist between the receptors [96]. It has been suggested that PRLR activation induces increased expression of suppressor-of-cytokine signaling (SOCS) proteins which directly inhibit STAT3-mediated pathways downstream of the leptin receptor [96]. However, other studies suggest no interaction between PRLR and the leptin receptor, as demonstrated by normal responses exhibited by the *Prlr*^{-/-} mice exposed to a leptin antagonist [91]. Such discrepancies may have arisen because prolactin-mediated effects require insulin coexpression [25,28].

In humans, sustained hyperprolactinemia caused by antipsychotic drugs or prolactinoma is associated with weight gain and insulin resistance [97]. This can be corrected by administration of dopamine agonists such as bromocriptine [98]. Furthermore, two SNPs located close to the *PRL* gene have been associated with increased risk of obesity [99,100]. Examination of larger cohorts with detailed phenotyping may provide fresh insight into PRLR's role in adipocytes.

Role of PRLR in immune responses

PRLR is expressed on all leukocytes of the immune system, and highly expressed in the spleen and thymus [101]. Although numerous *in vitro* studies have demonstrated prolactin can activate immune system cells, this remains controversial, with evidence indicating these findings may have no relevance in physiological settings, not least because mouse models fail to replicate these responses.

Studies demonstrate that prolactin enhances T-cell activation by several means including: 1) activation of the earliest known T-cell surface antigen, CD69, that is necessary for prolonged T-cell

activation and proliferation [102,103]; 2) activation of CD25, the α -chain of the interleukin (IL)-2-receptor, that regulates proliferation and expansion of T-cell subsets [103]; 3) phosphorylation and activation of the T-cell receptor component CD3, and second messenger kinases Fyn and ZAP70 [64,104,105]; 4) enhanced expression of CD40, CD80 and CD86 co-stimulatory molecules on antigen presenting cells [106]; 5) induction of cytokines involved in enhancing T-cell responses including IL-1, IL-12 IL-16 and interferon- γ [106,107]; and 6) sensitivity of immune responses to dopamine agonists [106]. It is largely accepted that prolactin is unable to initiate these responses in isolation, and more likely acts as an adjuvant to existing immune responses, evidence of which is provided by enhanced activation of T-cell pathways in response to concanavalin-A, lipopolysaccharide and phytohaemagglutinin (PHA) stimuli [107–109].

Autoimmune states provide a model to investigate prolactin's role in immunity. Multiple sclerosis (MS) is one such state, which is more prevalent in females, indicating a possible hormone-driven effect. Pregnant MS patients have increased relapse rates within the first three months post-partum, correlating with increased prolactin levels [110]. Similarly in systemic lupus erythematosus (SLE), elevated prolactin levels in patients correlate with disease severity [110] and treatment with bromocryptine relieved symptoms [106]. However, SLE mouse models were unable to demonstrate an enhancement of the condition in the presence of prolactin [110].

The controversies in this field not only lie in these autoimmune discrepancies. Much of the evidence for prolactin-mediated immune responses are derived from *in vitro* studies using peripheral blood mononuclear cells (PMBCs) or immortalized cells such as Jurkat T-cells, which may not reflect the physiological state. *In vivo* studies using *Prl*^{-/-} and *Prlr*^{-/-} mouse models have cast doubt on prolactin-mediated immune modulatory functions. *Prl*^{-/-} mice have comparable levels of CD4⁺ and CD8⁺ cells to wild-type littermates [111]. Furthermore, PHA-stimulated T-cell and B-cell responses were only impaired in *Prl*^{-/-} mice following thermal stress [108], indicating PRL may not have a role in physiological states. *Prlr*^{-/-} mice have no differences in either pro- or pre-B-cells, mature circulating B-cells, early T-cell precursors, immunoglobulin subclasses or NK-cells compared to wild-type littermates [112]. In addition, combination treatments of PRL and concanavalin-A or *Listeria monocytogenes* were unable to enhance immune responses above that seen with pathogen alone [112].

Finally, studies of immune responses in affected members of the hyperprolactinemic family with the PRLR-H188R mutation indicated no changes in immune cell subsets [31]. Furthermore, prolactin did not enhance T-cell responses to PHA in PMBCs isolated from affected family members [31]. These studies indicate that the role of prolactin in immune responses may be more complicated than originally proposed, with the possibility that prolactin responses are mediated by another receptor.

Summary

Research within the last two decades has identified new and unexpected roles for prolactin and its receptor, governed by multiple signaling pathways. Potential pathogenic roles in infertility, cancer, diabetes and obesity raise the possibility that PRLR and/or its downstream pathways will likely lead to novel therapies in these vital and highly prevalent disease states.

References

[1] Foitzik K, Krause K, Nixon AJ, Ford CA, Ohnemus U, Pearson AJ, et al. Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. *Am J Pathol* 2003;162:1611–21.

[2] Garcia-Caballero T, Morel G, Gallego R, Fraga M, Pintos E, Gago D, et al. Cellular distribution of prolactin receptors in human digestive tissues. *J Clin Endocrinol Metab* 1996;81:1861–6.

[3] Nagano M, Chastre E, Choquet A, Bara J, Gerspach C, Kelly PA. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. *Am J Physiol* 1995;268:G431–442.

[4] Rivera JC, Aranda J, Riesgo J, Nava G, Thebault S, Lopez-Barrera F, et al. Expression and cellular localization of prolactin and the prolactin receptor in mammalian retina. *Exp Eye Res* 2008;86:314–21.

[5] Huang C, Snider F, Cross JC. Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. *Endocrinology* 2009;150:1618–26.

[6] Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. *J Clin Endocrinol Metab* 2003;88:1804–8.

[7] Brooks CL. Molecular mechanisms of prolactin and its receptor. *Endocr Rev* 2012;33:504–25.

[8] Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. *Endocr Rev* 1998;19:225–68.

[9] Baran N, Kelly PA, Binart N. Characterization of a prolactin-regulated gene in reproductive tissues using the prolactin receptor knockout mouse model. *Biol Reprod* 2002;66:1210–8.

[10] Eyal O, Jomani JB, Kessler C, Goffin V, Handwerger S. Autocrine prolactin inhibits human uterine decidualization: a novel role for prolactin. *Biol Reprod* 2007;76:777–83.

[11] Oakes SR, Rogers RL, Naylor MJ, Ormandy CJ. Prolactin regulation of mammary gland development. *J Mammary Gland Biol Neoplasia* 2008;13:13–28.

[12] Morales FC, Hayashi Y, van Pelt CS, Georgescu MM. NHERF1/EBP50 controls lactation by establishing basal membrane polarity complexes with prolactin receptor. *Cell Death Dis* 2012;3:e391.

[13] Garcia-Martinez JM, Calcabrini A, Gonzalez L, Martin-Forero E, Agullo-Ortuno MT, Simon V, et al. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. *Cell Signal* 2010;22:415–26.

[14] Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. *Mol Cell Biol* 2004;24:5510–20.

[15] Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, et al. Socs2 and elf5 mediate prolactin-induced mammary gland development. *Mol Endocrinol* 2006;20:1177–87.

[16] Ormandy CJ, Naylor M, Harris J, Robertson F, Horseman ND, Lindeman GJ, et al. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. *Genes Dev* 2003;17:3297–3323.

[17] Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. *Genes Dev* 2008;22:711–21.

[18] Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. *Proc Natl Acad Sci U S A* 1997;94:7239–44.

[19] Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. *Cell* 1998;93:841–50.

[20] Saunier E, Dif F, Kelly PA, Edery M. Targeted expression of the dominant-negative prolactin receptor in the mammary gland of transgenic mice results in impaired lactation. *Endocrinology* 2003;144:2669–75.

[21] Goffin V, Binart N, Touraine P, Kelly PA. Prolactin: the new biology of an old hormone. *Annu Rev Physiol* 2002;64:47–67.

[22] Harris J, Stanford PM, Oakes SR, Ormandy CJ. Prolactin and the prolactin receptor: new targets of an old hormone. *Ann Rev* 2004;36:414–25.

[23] Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, et al. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. *Dev Biol* 2001;229:163–75.

[24] Binart N, Helloc C, Ormandy CJ, Barra J, Clement-Lacroix P, Baran N, et al. Rescue of preimplantary egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. *Endocrinology* 2000;141:2691–7.

[25] Bachelot A, Beaufaron J, Servel N, Kedzia C, Monget P, Kelly PA, et al. Prolactin independent rescue of mouse corpus luteum life span: identification of prolactin and luteinizing hormone target genes. *Am J Physiol Endocrinol Metab* 2009;297:E676–684.

[26] Grosdemouge I, Bachelot A, Lucas A, Baran N, Kelly PA, Binart N. Effects of deletion of the prolactin receptor on ovarian gene expression. *Reprod Biol Endocrinol* 2003;1:12.

[27] Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. *Endocrinology* 2011;152:526–35.

[28] Reese J, Binart N, Brown N, Ma WG, Paria BC, Das SK, et al. Implantation and decidualization defects in prolactin receptor (PRLR)-deficient mice are mediated by ovarian but not uterine PRLR. *Endocrinology* 2000;141:1872–81.

[29] Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, et al. Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. *J Cell Biol* 2001;155:531–42.

- [30] Devi YS, Halperin J. Reproductive actions of prolactin mediated through short and long receptor isoforms. *Mol Cell Endocrinol* 2014;382:400–10.
- [31] Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, et al. Mutant prolactin receptor and familial hyperprolactinemia. *N Engl J Med* 2013;369:2012–20.
- [32] Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice over-expressing the prolactin gene develop dramatic enlargement of the prostate gland. *Endocrinology* 1997;138:4410–5.
- [33] Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. *Endocrinology* 1998;139:3691–5.
- [34] Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. *Nat Rev Urol* 2011;8:597–607.
- [35] Bartke A. Role of growth hormone and prolactin in the control of reproduction: what are we learning from transgenic and knock-out animals? *Steroids* 1999;64:598–604.
- [36] Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, et al. Prostate development and carcinogenesis in prolactin receptor knockout mice. *Endocrinology* 2003;144:3196–205.
- [37] Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1999;91:629–34.
- [38] Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. *Cancer Lett* 2006;243:160–9.
- [39] Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women. *Cancer Res* 2006;66:2476–82.
- [40] Ferreira M, Mesquita M, Quaresma M, Andre S. Prolactin receptor expression in gynaecomastia and male breast carcinoma. *Histopathology* 2008;53:56–61.
- [41] Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. *Cancer Res* 2009;69:3165–72.
- [42] Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. *Mol Cell Endocrinol* 2009;307:1–7.
- [43] Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. *Oncogene* 2000;19:1072–6.
- [44] Nitze LM, Galsgaard ED, Din N, Lund VL, Rasmussen BB, Berchtold MW, et al. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. *Breast Cancer Res Treat* 2013;142:31–44.
- [45] Nyante SJ, Faupel-Badger JM, Sherman ME, Pfeiffer RM, Gaudet MM, Falk RT, et al. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland. *Breast Cancer Res* 2011;13:R42.
- [46] Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F. Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma? *Curr Med Res Opin* 2004;20:533–40.
- [47] Vavilavek A, Hemminki K, Bartram CR, Wagner K, Wappenschmidt B, Meindl A, et al. Association of prolactin and its receptor gene regions with familial breast cancer. *J Clin Endocrinol Metab* 2006;91:1513–9.
- [48] Lee SA, Haiman CA, Burt NP, Pooler LC, Cheng I, Kolonel LN, et al. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. *BMC Med Genet* 2007;8:72.
- [49] Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. *Proc Natl Acad Sci U S A* 2008;105:14533–8.
- [50] Courtillot C, Chakhtoura Z, Bogorad R, Genestie C, Bernichtein S, Badachi Y, et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. *J Clin Endocrinol Metab* 2010;95:271–9.
- [51] Mong FY, Kuo YL, Liu CW, Liu WS, Chang LC. Association of gene polymorphisms in prolactin and its receptor with breast cancer risk in Taiwanese women. *Mol Biol Rep* 2011;38:4629–36.
- [52] Bratthauer GL, Strauss BL, Tavassoli FA. STAT 5a expression in various lesions of the breast. *Virchows Arch* 2006;448:165–71.
- [53] Bratthauer GL, Strauss BL, Barner R. Reversed expression of the JAK/STAT pathway related proteins prolactin receptor and STAT5a in normal and abnormal breast epithelial cells. *Breast Cancer* 2008;1:7–14.
- [54] Arendt LM, Rugowski DE, Grafvallner-Huseuth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. *Breast Cancer* 2011;13:R11.
- [55] Barcus CE, Keely PJ, Eliceiri KW, Schuler LA. Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. *J Biol Chem* 2013;288:12722–32.
- [56] Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. *Cancer Res* 2006;66:1824–32.
- [57] Barcus CE, Holt EC, Keely PJ, Eliceiri KW, Schuler LA. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. *PLoS One* 2015;10:e0116891.
- [58] Frasier J, Gibori G. Prolactin regulation of estrogen receptor expression. *Trends Endocrinol Metab* 2003;14:118–23.
- [59] Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. *J Steroid Biochem Mol Biol* 2004;88:69–77.
- [60] Dong J, Tsai-Morris CH, Dufau ML. A novel estradiol/estrogen receptor alpha-dependent transcriptional mechanism controls expression of the human prolactin receptor. *J Biol Chem* 2006;281:18825–36.
- [61] Li Y, Clevenger CV, Minkovsky N, Kumar KG, Raghunath PN, Tomaszewski JE, et al. Stabilization of prolactin receptor in breast cancer cells. *Oncogene* 2006;25:1896–902.
- [62] Lim JH, Kim TY, Kim WH, Park JW. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways. *Breast Cancer Res Treat* 2011;130:19–27.
- [63] Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. *Breast Cancer Res* 2012;14:R130.
- [64] Clevenger CV, Medaglia MV. The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. *Mol Endocrinol* 1994;8:674–81.
- [65] Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. *Am J Pathol* 1995;146:695–705.
- [66] Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. *Cancer Res* 1995;55:2591–5.
- [67] Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. *Oncogene* 2003;22:4664–74.
- [68] Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. *J Endocrinol* 2009;203:99–110.
- [69] Lopez-Pulido EI, Munoz-Valle JF, Del Toro-Arreola S, Jave-Suarez LF, Bueno-Topete MR, Estrada-Chavez C, et al. High expression of prolactin receptor is associated with cell survival in cervical cancer cells. *Cancer Cell Int* 2013;13:103.
- [70] Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. *Endocrinology* 2003;144:2269–78.
- [71] Arumugam R, Fleenor D, Freemark M. Knockdown of prolactin receptors in a pancreatic beta cell line: effects on DNA synthesis, apoptosis, and gene expression. *Endocrine* 2014;46(3):568–76.
- [72] Labriola L, Montor WR, Krogh K, Lojudice FH, Genzini T, Goldberg AC, et al. Beneficial effects of prolactin and laminin on human pancreatic islet-cell cultures. *Mol Cell Endocrinol* 2007;263:120–33.
- [73] Huang C. Wild-type offspring of heterozygous prolactin receptor-null female mice have maladaptive beta-cell responses during pregnancy. *J Physiol* 2013;591:1325–38.
- [74] Friedrichsen BN, Galsgaard ED, Nielsen JH, Moldrup A. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5). *Mol Endocrinol* 2001;15:136–48.
- [75] Yu J, Xiao F, Zhang Q, Liu B, Guo Y, Lv Z, et al. PRLR regulates hepatic insulin sensitivity in mice via STAT5. *Diabetes* 2013;62:3103–13.
- [76] Lee JY, Gavrilova O, Davani B, Na R, Robinson GW, Hennighausen L. The transcription factors Stat5a/b are not required for islet development but modulate pancreatic beta-cell physiology upon aging. *Biochim Biophys Acta* 2007;1773:1455–61.
- [77] Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr IM, et al. Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase. *J Biol Chem* 1998;273:15719–26.
- [78] Amaral ME, Cunha DA, Anhe GF, Ueno M, Carneiro EM, Velloso LA, et al. Participation of prolactin receptors and phosphatidylinositol 3-kinase and MAP kinase pathways in the increase in pancreatic islet mass and sensitivity to glucose during pregnancy. *J Endocrinol* 2004;183:469–76.
- [79] Weinhaus AJ, Stout LE, Bhagoo NV, Brelje TC, Sorenson RL. Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. *J Endocrinol* 2007;193:367–81.
- [80] Eto K, Nishimura W, Oishi H, Udagawa H, Kawaguchi M, Hiramoto M, et al. MafA is required for postnatal proliferation of pancreatic beta-cells. *PLoS One* 2014;9:e104184.
- [81] Plank JL, Frist AY, LeGrone AW, Magnuson MA, Labosky PA. Loss of Foxd3 results in decreased beta-cell proliferation and glucose intolerance during pregnancy. *Endocrinology* 2011;152:4589–600.
- [82] Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, et al. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. *Mol Cell Biol* 2005;25:3752–62.
- [83] Hughes E, Huang C. Participation of Akt, menin, and p21 in pregnancy-induced beta-cell proliferation. *Endocrinology* 2011;152:847–55.
- [84] Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. *Science* 2007;318:806–9.
- [85] Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. *Nat Med* 2010;16:804–8.

- [86] Schraenen A, Lemaire K, de Faudeur G, Hendrickx N, Granvik M, Van Lommel L, et al. Placental lactogens induce serotonin biosynthesis in a subset of mouse beta cells during pregnancy. *Diabetologia* 2010;53:2589–99.
- [87] Goyvaerts L, Lemaire K, Arijis I, Auffret J, Granvik M, Van Lommel L, et al. Prolactin receptors and placental lactogen drive male mouse pancreatic islets to pregnancy-related mRNA changes. *PLoS One* 2015;10:e0121868.
- [88] Ohara-Imaizumi M, Kim H, Yoshida M, Fujiwara T, Aoyagi K, Toyofuku Y, et al. Serotonin regulates glucose-stimulated insulin secretion from pancreatic beta cells during pregnancy. *Proc Natl Acad Sci U S A* 2013;110:19420–5.
- [89] Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. *Endocrinology* 2002;143:1378–85.
- [90] Le TN, Elsea SH, Romero R, Chaiworapongsa T, Francis GL. Prolactin receptor gene polymorphisms are associated with gestational diabetes. *Genet Test Mol Biomarkers* 2013;17:567–71.
- [91] Carre N, Solomon G, Gertler A, Binart N. Effects of high affinity leptin antagonist on prolactin receptor deficient male mouse. *PLoS One* 2014;9:e91422.
- [92] Freemark M, Fleenor D, Driscoll P, Binart N, Kelly P. Body weight and fat deposition in prolactin receptor-deficient mice. *Endocrinology* 2001;142:532–7.
- [93] Viengchareun S, Servel N, Feve B, Freemark M, Lombes M, Binart N. Prolactin receptor signaling is essential for perinatal brown adipocyte function: a role for insulin-like growth factor-2. *PLoS One* 2008;3:e1535. <http://dx.doi.org/10.1371/journal.pone.0001535>.
- [94] Viengchareun S, Bouzinba-Segard H, Laigneau JP, Zennaro MC, Kelly PA, Bado A, et al. Prolactin potentiates insulin-stimulated leptin expression and release from differentiated brown adipocytes. *J Mol Endocrinol* 2004;33:679–91. <http://dx.doi.org/10.1677/jme.1.01563>.
- [95] Augustine RA, Grattan DR. Induction of central leptin resistance in hyperphagic pseudopregnant rats by chronic prolactin infusion. *Endocrinology* 2008;149:1049–55.
- [96] Nagaishi VS, Cardinali LI, Zampieri TT, Furigo IC, Metzger M, Donato Jr J. Possible crosstalk between leptin and prolactin during pregnancy. *Neuroscience* 2014;259:71–83. <http://dx.doi.org/10.1016/j.neuroscience.2013.11.050>.
- [97] Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. *Pharmacopsychiatry* 2000;33:81–8.
- [98] Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. *Eur J Endocrinol* 2002;147:77–84.
- [99] Meyre D, Delplanque J, Chevre JC, Lecoecur C, Lobbens S, Gallina S, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat Genet* 2009;41:157–9.
- [100] Nilsson L, Olsson AH, Isomaa B, Groop L, Billig H, Ling C. A common variant near the PRL gene is associated with increased adiposity in males. *Mol Genet Metab* 2011;102:78–81.
- [101] Dogusan Z, Book ML, Verdood P, Yu-Lee LY, Hooghe-Peters EL. Prolactin activates interferon regulatory factor-1 expression in normal lympho-hemopoietic cells. *Eur Cytokine Netw* 2000;11:435–42.
- [102] Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. *Stem Cells* 1994;12:456–65.
- [103] Takizawa K, Kitani S, Takeuchi F, Yamamoto K. Enhanced expression of CD69 and CD25 antigen on human peripheral blood mononuclear cells by prolactin. *Endocr J* 2005;52:635–41.
- [104] Montgomery DW, Krumenacker JS, Buckley AR. Prolactin stimulates phosphorylation of the human T-cell antigen receptor complex and ZAP-70 tyrosine kinase: a potential mechanism for its immunomodulation. *Endocrinology* 1998;139:811–4. <http://dx.doi.org/10.1210/endo.139.2.5913>.
- [105] Krumenacker JS, Montgomery DW, Buckley DJ, Gout PW, Buckley AR. Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells. *Endocrine* 1998;9(3):313–20.
- [106] Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. *Autoimmun Rev* 2007;6:537–42.
- [107] Matalka KZ. Prolactin enhances production of interferon-gamma, interleukin-12, and interleukin-10, but not of tumor necrosis factor-alpha, in a stimulus-specific manner. *Cytokine* 2003;21:187–94.
- [108] Dugan AL, Thellin O, Buckley DJ, Buckley AR, Ogle CK, Horseman ND. Effects of prolactin deficiency on myelopoiesis and splenic T lymphocyte proliferation in thermally injured mice. *Endocrinology* 2002;143:4147–51.
- [109] Gagnerault MC, Touraine P, Savino W, Kelly PA, Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. *J Immunol* 1993;150:5673–81.
- [110] Costanza M, Musio S, Abou-Hamdan M, Binart N, Pedotti R. Prolactin is not required for the development of severe chronic experimental autoimmune encephalomyelitis. *J Immunol* 2013;191:2082–8.
- [111] Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, et al. Defective mammapoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. *EMBO J* 1997;16:6926–35.
- [112] Bouchard B, Ormandy CJ, Di Santo JP, Kelly PA. Immune system development and function in prolactin receptor-deficient mice. *J Immunol* 1999;163:576–82.